|
|
Quick Links and References
Quick Links
References
The role of PPARs
- Ferré P. The biology of peroxisome proliferator-activated receptors: relationship with lipid metabolism and insulin sensitivity. Diabetes. 2004;53(suppl 1)
:S43-S50. Available at: http://diabetes.diabetesjournals.org
- Marx N, Duez H, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors and atherogenesis: Regulators of gene expression in vascular cells. Circ Res. 2004;94:1168-1178. Available at: http://circres.ahajournals.org
- Jackson SM, Parhami F, Xi XP, et al. Peroxisome proliferator-activated receptor activators target human endothelial cells to inhibit leukocyte-endothelial cell interaction. Arterioscler Thromb Vasc Biol. 1999;19:2094-2104. Available at: http://atvb.ahajournals.org
- Barbier O, Torra IP, Duguay Y. Pleiotropic actions of peroxisome proliferator-activated receptors in lipid metabolism and atherosclerosis. Arterioscler Thromb Vasc Biol. 2002;22:717-726. Available at: http://atvb.ahajournals.org
Addressing core defects
- Kahn SE. The importance of the β-cell in the pathogenesis of type 2 diabetes mellitus. Am J Med. 2000;108(suppl 6A):2S-8S. Available at: http://www.amjmed.com
Microvascular and macrovascular complications
- Nesto RW, Bell D, Bonow RO, et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Circulation. 2003;108:
2941-2948. Available at: http://circ.ahajournals.org
- Lyon CJ, Law RE, Hsueh WA. Minireview: adiposity, inflammation, and atherogenesis. Endocrinology. 2003;144:2195-2200. Available at: http://endo.endojournals.org
- Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339:229-234. Available at: http://content.nejm.org
- Stratton IM, Adler AI, Neil HA, et al, on behalf of the UK Prospective Diabetes Study Group. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321:405-412. Available at: http://www.bmj.com
The importance of lipids
- Lamarche B, Tchernof A, Moorjani S, et al. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men: prospective results from the Quebec Cardiovascular Study. Circulation. 1997;95:69-75. Available at: http://circ.ahajournals.org
New treatment guidelines
- Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetes Care. 2006;29:1963-1972. Available at: http://care.diabetesjournals.org
Treatment goals and guidelines
- American Diabetes Association. Standards of medical care in diabetes–2007. Diabetes Care. 2007;30(suppl 1):S4-S41. Available at: http://care.diabetesjournals.org
- Davidson JA, Blonde L, Jellinger PS, Lebovitz HE, Parkin CG. Road map for the prevention and treatment of type 2 diabetes. American Association of Clinical Endocrinologists website. Available at: http://www.aace.com
- Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497. Available at: http://jama.ama-assn.org
Patient Compliance Information
- LaRosa JH, LaRosa JC. Enhancing drug compliance in lipid-lowering treatment. Arch Fam Med. 2000;9:1169-1175. Available at: http://archfami.ama-assn.org
|